<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>MEXILETINE</b></p>

<p><b>See also: antiarrythmic agents</b></p>

<p><b>See also: class l antiarrhythmics (except lidocaine)</b></p>

<p><b>From the French ANSM drug interactions document of </b></p>

<p><b>September 2016, pp. 154-155</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>MEXILETINE</b></p>

<p><b>RxNorm: 6926</b></p>

<p><b>ATC: C01BB02</b></p></td>
<td valign="top"><p><b>CAFFEINE </b></p>

<p><b>RxNorm: 1886</b></p>

<p><b>ATC: </b></p>

<p><b>N06BC01 V04CG30</b></p></td>
<td valign="top"><p>Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine</p></td>
<td valign="top"><p><b>Take into account</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>MEXILETINE</b></p>

<p><b>RxNorm: 6926</b></p>

<p><b>ATC: C01BB02</b></p></td>
<td valign="top"><p><b>FLUVOXAMINE</b></p>

<p><b>RxNorm: 42355 </b></p>

<p><b>ATC: N06AB08</b></p></td>
<td valign="top"><p>Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and EKG. Adjustment of the dosage of the mexiletine during the treatment with the fluvoxamine and after it is stopped<b>.</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>MEXILETINE</b></p>

<p><b>RxNorm: 6926</b></p>

<p><b>ATC: C01BB02</b></p></td>
<td valign="top"><p><b>PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>N03AB</b></p></td>
<td valign="top"><p>Decrease of the antiarrhythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the mexiletine; if there is reason for it, adjustment of the dosage of the mexiletine during the treatment with the phenytoin and after it is stopped<b>.</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>MEXILETINE</b></p>

<p><b>RxNorm: 6926</b></p>

<p><b>ATC: C01BB02</b></p></td>
<td valign="top"><p><b>THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>R03DA</b></p></td>
<td valign="top"><p>Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the mexiletine and after it is stopped<b>.</b></p></td>
</tr>

</tbody>
</table>

